uniQure Announces Proposed Public Offering

Core Viewpoint - uniQure N.V. has initiated an underwritten public offering of its ordinary shares and pre-funded warrants, with the potential for underwriters to purchase an additional 15% of shares at the public offering price [1][2]. Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including a gene therapy for hemophilia B, which marks a significant milestone in genomic medicine [5]. Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. - The securities are being offered under an automatically effective shelf registration statement filed with the SEC on January 7, 2025, with a preliminary prospectus supplement to be filed [3]. Underwriter Information - Leerink Partners is acting as the bookrunning manager for the proposed offering [2].